Boltz, which is developing open frontier AI models for biomolecular research, raised a $28M seed led by Zetta, Amplify, and a16z at a valuation of $125M
While the newest AlphaFold model took a leap forward in 2024 by predicting structures of nearly all biomolecules instead of just proteins, it also took a step back in openness.
We co-led the $28M seed round for @boltz_bio because we believe open models, usable software, and partnership (not competition) with academia and pharma will make AI a key piece of drug discovery and development. Hundreds of thousands of scientists use Boltz across pharma, [image…
Just days into 2026, our business model entry on SaaS for pharma is looking out of date. Noetik, Chai and Boltz all securing 8-fig model license deals. Some non-exclusive! Time will tell if it's a fad/the ROI pans out. If it does it's the first hint of what we saw w Wayve & AVs […
Congratulations to the Boltz team on this bonanza of announcements. Founded by researchers at the MIT Jameel Clinic (@AIHealthMIT), Boltz continues to push the boundaries of small-molecule and protein design, accelerating the development of new medicines. 🚀
We're excited to announce that we're co-leading a $28M Seed round in Boltz PBC. @boltz_bio comes out of research at MIT from Gabriele Corso, Jeremy Wohlwend, and Saro Passaro. They've built frontier open-source AI models for biomolecular research that saw explosive growth in [ima…